Skip to main content
SpringerLink
Log in

Challenges in Acute Ischemic Stroke Clinical Trials

  • Stroke (C Sila, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

There have been only 3 positive Phase III randomized clinical trials in acute ischemic stroke, all reperfusion therapies (NINDS; PROACT II; ECASS III). The only approved acute stroke therapy is <3-hour IV tPA. Although numerous compounds have shown benefit in animal models of brain infarction, there has never been a positive Phase III randomized clinical trial of a neuroprotectant in acute ischemic stroke. There are many challenges to acute stroke clinical trials but chief among these are the very short therapeutic window (“time is brain”) and the issue of stroke heterogeneity. Stroke is a syndrome and only a very small percentage of all stroke patients present to hospitals in time to consider reperfusion therapy. Many drugs have been rushed to trial prematurely based on inadequate preclinical testing. Many trials have been seriously underpowered due to overly optimistic treatment expectations and the risk of brain hemorrhage has precluded aggressive multimodal treatment strategies. Rather than simply relying on a clock, new imaging methods are being developed to identify patients with “tissue at risk” and “salvageable brain” regardless of time of stroke onset. The 7 STAIR conferences have been convened to address these and other challenges to acute ischemic stroke trial design and completion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.

    Article  Google Scholar 

  2. • Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, for the ECASS Investigators, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29. ECASS III established clinical efficacy of IV tpa up to 4.5 hours in selected patients.

    Article  PubMed  CAS  Google Scholar 

  3. Furlan AJ, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA. 1999;282:2003–11.

    Article  PubMed  CAS  Google Scholar 

  4. •• The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 hours of acute ischemic stroke (the third international stroke trial IST-3): a randomized controlled trial. Lancet. 2012. doi:101016/S0140-6736(12)60768-5. Published online, Largest randomized trial of IV tpa. No benefit of IV tpa at 6 hours from stroke onset based on primary endpoint.

  5. •• IMS3 A Descriptive Study of Interventional Management of Stroke III Trial Investigator recruitment enhancement strategies. Stroke. 2012;43:A3192. Compares standard IV tpas < 3 hours to IV tpa plus IA intervention using 5 different IA techniques. Recently halted due to futility.

  6. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467.

    Article  PubMed  Google Scholar 

  7. The GUSTO Investigators. An international randomized trial comparing 4 thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–82.

    Article  Google Scholar 

  8. Muir KW. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke. 2002;33:1545–50.

    Article  PubMed  Google Scholar 

  9. Furlan AJ, Acute Stroke Trials. Strengthening the underpowered. Stroke. 2002;33:1450–1.

    Article  PubMed  Google Scholar 

  10. • Fisher M. New approaches to neuroprotective drug development. Stroke. 2011;42 Suppl 1:S24–7. Problems in neuroprotectant trial design with potential solutions.

    Article  PubMed  Google Scholar 

  11. • Donnan GA. A new road map for neuroprotection. Stroke. 2008;39:242–8. Problems in neuroprotectant trial design with potential solutions.

    Article  PubMed  Google Scholar 

  12. Furlan AJ, Fisher M. Devices, drugs, and the Food and Drug Administration: increasing implications for ischemic stroke. Stroke. 2005;36:398–9.

    Article  PubMed  Google Scholar 

  13. • Furlan AJ. Ethics and feasibility of placebo-controlled interventional acute stroke trials. Stroke. 2009:e533–4. Highlights ethical and feasibility issues complicating the design and completion of stroke IA reperfusion trials.

  14. • Donnan GA, Davis SM. The ethics of thrombolytic trials beyond 3 (or 4.5) hours. Randomized controlled trials are required to change clinical practice. Stroke. 2009;40:1545. Justification for further stroke IA reperfusion trials.

    Article  PubMed  Google Scholar 

  15. Stroke Therapy Academic Industry Roundtable (Fisher M, Chair). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752–8.

    Article  Google Scholar 

  16. Stroke Therapy Academic Industry Roundtable (Fisher M, Chair). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001;32:1598–606.

    Article  Google Scholar 

  17. Fisher M. Recommendations for advancing development of acute stroke therapies. for the Stroke Therapy Academic Industry Roundtable. Stroke. 2003;34:1539–46.

    Article  PubMed  CAS  Google Scholar 

  18. Fisher M. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Roundtable. Stroke. 2005;36:1808–13.

    Article  PubMed  Google Scholar 

  19. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S. Recommendations from STAIR V meeting on acute stroke trials, technology, and outcomes. Stroke. 2007;38:245–8.

    Article  PubMed  Google Scholar 

  20. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke. 2009;40:2594–600.

    Article  PubMed  Google Scholar 

  21. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, et al. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial, and neuroprotective therapies. Stroke. 2011;42:2645–50.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, 44106, USA

    Anthony J. Furlan

Authors
  1. Anthony J. Furlan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony J. Furlan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Furlan, A.J. Challenges in Acute Ischemic Stroke Clinical Trials. Curr Cardiol Rep 14, 761–766 (2012). https://doi.org/10.1007/s11886-012-0311-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-012-0311-9

Keywords

Search

Navigation